GlaxoSmithKline (GSK)

44.38 +0.10  +0.23%  May 29, 5:19PM Go Pro
Watch this stock

GlaxoSmithKline Altman Z-Score: 2.902

Get Interactive Chart for

View GSK Altman Z-Score with YCharts Pro.




Start My 14-Day Free Trial We respect your privacy. We will never share your email address.
document.write('');

Access these YCharts Pro features:

  • Export any data you want
  • Save any chart as an image
  • Utilize advanced screener power
  • View 30 years of financial history
  • over 90 advanced calculations
  • Enjoy an advertising free experience
and much more...

GSK Altman Z-Score Rankings

Overall 53rd percentile 1641 of 3549
Sector 48th percentile 221 of 433 in Healthcare
Industry 41st percentile 10 of 17 in Drug Manufacturers - Major

GSK Altman Z-Score Range, Past 5 Years

Minimum 2.360 Mar 2011
Maximum 4.744 Jun 2007
Average 3.064

About Altman Z-Score

CAUTION: The Altman Z-Score is meant to be applied only to manufacturing firms that are near bankruptcy. It was not based on a sample including non-manufacturing firms (service firms, banks, etc.). Use it at your own risk with those companies, but beware that bankruptcy probabilities may be misstated.

The Altman Z-Score helps investors to gauge the probability of a company going bankrupt. Generally, firms with a score above 3.00 have a low probability of bankruptcy, and those with a Z-Score of less than 1.81 have a relatively high probability of bankruptcy.

Note that this is a probabilistic model, so it will not classify perfectly.

The score was first published in a 1968 paper by Edward Altman titled "Financial Ratios, Discriminant Analysis and the Prediction of Corporate Bankruptcy."

Altman re-tested the model in a 2000 paper titled "Predicting financial distress of companies: Revisiting the Z-score and Zeta models". The paper showed that the model still had utility for looking at manufacturers, though the number of misclassifications did increase over time.
Learn More

GSK News

@mydanilo It had nothing to do with those news. That was already priced in. Seems like Patent news regarding $TEVA and $GSK was the trigger.
about 6 hours ago by mitrado
$AMRN up following news that $Teva and $PRX lost a bid to sell the generic form of $GSK Lovaza. http://stks.co/41F0
about 8 hours ago by abubnic
Auxilium Pharma Sues Watson
May 29, 12:45PM
Teva Issues 2012 Outlook
May 29, 11:00AM
4 Stocks Buffett May Be Buying in Europe
May 25, 12:21PM Investor Place
Finding a Pathway to Approval
May 24, 2:53PM Fool
$GSK reacts to $HGSI poison pill. Stubborn, or what? It seems they do not want to get pushed or pulled.
about 7 days ago by OysterX
20 Giants for a 6% Dividend Yield
May 21, 9:07AM Fool
@xjun "totally betrayed" $AMRN says: "Sorry, it's not personal. Look at some of my neighbours: $ONTY, $SPPI, $NVAX, $GSK, $TEVA, $CELG ..."
about 12 days ago by mitrado
Why U.K. Bonds Are for Losers
May 17, 6:07PM Fool
Still think that $GSK will not succeed with $HGSI takeover at 13/share. They will increase the offer price, but probably not above 15.
about 13 days ago by OysterX
News related to $GSK, currently 0.0% since open: 'Prestige Brands posts small fiscal 4Q loss' http://stks.co/3s9V
about 13 days ago by TradeBot
Gilead Sciences’ HIV Drugs Clear a Hurdle
May 17, 10:00AM Investor Place
$GSK Trametinib also in the spotlight at ASCO '12 with six presentations over 4 days. http://stks.co/3roL
about 13 days ago by abubnic
$GSK Dabrafenib getting its share of attention at ASCO '12 with 50 presentations over 4 days. http://stks.co/3roI
about 13 days ago by abubnic
$PFE $LLY $GSK So this is the condition some drug commercials warned us about! And we thought they were kidding. http://stks.co/3q2n
about 14 days ago by laughing_stock
Don't see $XNPT popping 100% like $ARNA did, not as glamorous and still has to settle with $GSK. They would get 10 million if still partnrd
about 14 days ago by Glopolon
5 Dividends to Reinvest
May 14, 10:34AM Fool
$ARNA -Big brand name companies may be interested in buyout $GSK $PFE $SNY $ABT First weight-loss drug in US may be approved in June $SPY $$
about 16 days ago by peterumble
$XNPT, No Debt, Drug has already been approved for RLS, so safety issues known. Court case with $GSK still out there, want settlement.
about 18 days ago by Glopolon
Some really tempting European stocks that pay healthy dividends $SNY $HBC $SI $ABB $SNY $GSK $RDS.B all above 4%
about 20 days ago by sld1986
$VVUS Racked With Losses, Vivus is Putting All Its Eggs in This Basket http://stks.co/3kNz $OREX $ARNA $PFE $LLY $GSK
about 20 days ago by DrNick
RT @JasonMilano8 $AMRN Here is a news about current CEO of Amarin selling his former company Reliant to ($GSK) in 2007: http://stks.co/3k0G
about 21 days ago by JasonMilano8
Breakfast Links | via @PointsnFigures http://stks.co/3jto $AMZN $GSK $HGSI $ZNGA
about 21 days ago by STNet
That's a surprise. $GSK goes hostile with $HGSI offer at 13. Did not expect that and am curious whether HGSI has something up its sleeve.
about 21 days ago by OysterX
$AMRN Here is a news about current CEO of Amarin selling his former company Reliant to GlaxoSmithKline ($GSK) in 2007: http://stks.co/3jYt
about 21 days ago by JasonMilano8
$XNPT, Only non-dopaminergic option for RLS, is the advantage over generics. If $XNPT can work things out with $GSK, this should be $5+
about 21 days ago by Glopolon
Huf Post: Two Drugs Harness Immune System To Fight Cancer. http://stks.co/3iDa $DNDN $BMY $AZN $ONTY $GSK
about 22 days ago by abubnic
@BioRunUp @GantosJ $XNPT, Hope that they can settle w/ $GSK, and if Astellas in Japan is competent, then $XNPT is looking good.
about 22 days ago by Glopolon
$XNPT Sounds like Astellas is going to be better partner than $GSK, Hope they can work things out with $GSK re: Horizant.
about 23 days ago by Glopolon
$XNPT $GSK, FDA PDUFA date June 9th for Horizant treating postherpetic neuralgia. Horizant already approved in Japan for restless leg synd.
about 25 days ago by Glopolon
Best Yielding Large Cap Healthcare Stocks + http://stks.co/3cMJ + $JNJ $PFE $NVS $MRK $GSK $SNY $NVO $UNH $BMY $TEVA $MDT $BAX $AGN $SYK
about 28 days ago by DividendYield

Recent Quotes

Symbol Price Chg Chg % Market Cap
GSK 44.38 +0.10 +0.23% 111.75B
GSIT 4.18 -0.02 -0.48% 120.25M
GSIG 11.98 +0.13 +1.10% 397.09M
GSI 0.9874 +0.12 +13.48%
GSH 16.41 +0.11 +0.67% 2.314B
GSB 2.06 -0.09 -4.19% 39.15M
GSAT 0.391 -0.01 -3.43% 120.61M
GS 97.82 +1.12 +1.16% 47.86B
GRZ 3.40 +0.11 +3.34% 195.89M
GRX 8.14 +0.04 +0.49%
You must be signed in to use watchlists.
Sign In or Register
Create Watchlist from Stock Quotes
Close